Study wrapper · #657
[Experimental hemorrhagic stroke: the study of neuropeptides (MIF, selank) in the intraperitoneal injection].
Editor's note
This is a small preclinical rat study of intracerebral hemorrhage, testing the tuftsin derivatives MIF (Thr-Lys-Pro) and Selank against saline. Hemorrhage was induced by injecting autologous blood into the basal nucleus; groups of just five animals each received saline, MIF (150 microg/kg/day), or Selank (300 microg/kg/day). Researchers reported that the peptides improved functional/neurological recovery without affecting hematoma volume or perifocal edema early on; by day 10, hematoma volume and edema had significantly decreased across all groups, and only the peptide-treated groups showed significant neurological improvement on the tests used. For Selank, this extends its neuroprotective/functional-recovery framing to a stroke model. Weigh it very cautiously: with n=5 per arm this is severely underpowered, edema resolved in all groups (including controls), and the between-group signal is limited to neurological scales. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
This study used a rat model of a brain bleed (intracerebral hemorrhage) to test two peptides, MIF and Selank, against a saltwater control. Researchers created the bleed by injecting the animal's own blood into a deep brain region, then followed the rats for 10 days with body-weight checks, neurological exams, and brain MRI scans. There were only five rats in each group. The peptides did not shrink the size of the bleed or the surrounding swelling in the first days. By day 10, the bleed and swelling had gone down significantly in all groups, including the control. However, only the rats given a peptide showed significant improvement on the neurological tests, and only the control group lost significant weight early on. With just five animals per group, this is a very small study, and much of the improvement (like reduced swelling) happened in the control too. It is a weak, early animal signal about functional recovery, not evidence for treating brain bleeds in people.